[Form 4/A] Rockwell Medical, Inc. (DE) Amended Insider Trading Activity

Rhea-AI Filing Summary

Form 144 filed for Datadog, Inc. (DDOG) discloses a planned sale of insider shares under Rule 144.

• Seller & volume: David Obstler intends to sell 15,000 Class A common shares, representing roughly 0.005 % of the 319,498,060 shares outstanding.
• Estimated proceeds: At an aggregate market value of $2.03 million, the transaction is scheduled for 07 July 2025 through broker Morgan Stanley Smith Barney LLC on the NASDAQ.
• Acquisition details: The shares derive from a 07 July 2025 stock-option exercise paid in cash.
• 10b5-1 activity: The filing lists six prior sales in the last three months under a 10b5-1 plan, totaling 105,016 shares and approximately $12.6 million in gross proceeds.

The filing contains the standard certification that the seller possesses no undisclosed material adverse information. There is no indication of new corporate developments, earnings data, or changes to capital structure; the document strictly concerns insider share dispositions.

Positive

• None.

Negative

• Continued insider selling—over 105 k shares sold in the last three months plus 15 k now planned—can be interpreted as weak insider confidence, albeit small relative to float.

Insights

Financial Analyst

TL;DR – Routine insider sale; small versus float, modest negative sentiment.

This Form 144 signals continued insider selling by David Obstler, who has already liquidated over 105 k shares in the prior quarter. The new 15 k-share notice is immaterial relative to the 319 M float, but cumulative sales near $14 M may raise eyebrows among momentum or governance-sensitive investors. The use of a 10b5-1 plan tempers concerns by framing transactions as pre-scheduled, and market impact should be negligible. Overall, the filing is not fundamentally impactful yet contributes to a slightly negative narrative on insider sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chole Timothy

(Last) (First) (Middle)

30142 WIXOM ROAD

(Street)

WIXOM MI 48393

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKWELL MEDICAL, INC. [ RMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and CCO

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/02/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		S(1)		2,868	D	$0.82	128,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024 in multiple trades at prices ranging from $0.80 to $0.83. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This form is being amended to check the required box for sales pursuant to a Rule 10b5-1 Plan.

	/s/ Megan Timmins, Attorney-in-fact for Timothy Chole	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Datadog (DDOG) shares are being sold under this Form 144?

15,000 Class A common shares are slated for sale.

What is the estimated value of the planned DDOG share sale?

The aggregate market value is $2,025,150 based on the filing.

When is the approximate sale date for the DDOG insider transaction?

The shares are expected to be sold on or about 07/03/2025.

How many Datadog shares has the insider sold in the past three months?

The filing lists 105,016 shares previously sold between 02 June 2025 and 30 June 2025.

What percentage of Datadog’s outstanding shares does the new sale represent?

Roughly 0.005 % of the 319,498,060 shares outstanding.

Which broker will handle the DDOG insider sale?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.